Pulmonary outcome prediction (POP) tools for cystic fibrosis patients.
about
Clinical applications of pulmonary delivery of antibioticsUnderstanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal studyOral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.State of progress in treating cystic fibrosis respiratory disease.Chest computed tomography scores of severity are associated with future lung disease progression in children with cystic fibrosis.Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosisEarly Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis.IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosisEarly Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 YearsStandardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.Effects of Autogenic Drainage on Sputum Recovery and Pulmonary Function in People with Cystic Fibrosis: A Systematic Review.Socioeconomic Status, Smoke Exposure, and Health Outcomes in Young Children With Cystic Fibrosis.Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.Hypoglycemia is common in children with cystic fibrosis and seen predominantly in females.
P2860
Q26996053-8EA87F2B-0017-48E3-A387-D62C0A4BEBC7Q28388812-B475F397-A99F-4E73-8701-2C38D671D14FQ33725822-98D42702-409C-4C13-8500-B199B4D01F6CQ34375926-6E227578-9501-41E3-A6E2-4163FC994251Q35528367-64F0437D-67D4-4F10-87D0-B801A45959C9Q36031045-5E89EDF6-0FEB-4661-8EDE-ECB9A232E127Q36050609-47B60372-53CC-498D-9946-0CFEB6D0D49DQ36827488-C3B5EC7C-99A4-4348-8DE7-CFDE7C3658F9Q37244642-A635B16B-F742-4C1D-B340-B84ACC45C78DQ38688865-1DB90061-E62A-42DD-A390-426CC2046BF7Q38922548-F6439804-4EF1-4C64-BB8F-D6C86FA001E2Q39017682-6EF016E0-873B-49D8-9F2F-6CDD6A8D285DQ39800405-1E218C9E-94E2-4599-8BCF-E3BE680F7663Q44016904-3B4AAA79-EB93-47CF-846B-271F14B835F5Q47938935-A536FB21-6CA9-47BA-B411-8B17A433DAF9
P2860
Pulmonary outcome prediction (POP) tools for cystic fibrosis patients.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Pulmonary outcome prediction (POP) tools for cystic fibrosis patients.
@ast
Pulmonary outcome prediction (POP) tools for cystic fibrosis patients.
@en
type
label
Pulmonary outcome prediction (POP) tools for cystic fibrosis patients.
@ast
Pulmonary outcome prediction (POP) tools for cystic fibrosis patients.
@en
prefLabel
Pulmonary outcome prediction (POP) tools for cystic fibrosis patients.
@ast
Pulmonary outcome prediction (POP) tools for cystic fibrosis patients.
@en
P2093
P2860
P356
P1476
Pulmonary outcome prediction (POP) tools for cystic fibrosis patients
@en
P2093
Eric Elkin
Jeffrey S Wagener
Joan R Jacobs
Michael W Konstan
Wayne J Morgan
P2860
P304
P356
10.1002/PPUL.21311
P577
2010-08-17T00:00:00Z